Advertisement Teva to discuss with FDA over contraceptive pill wider access - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Teva to discuss with FDA over contraceptive pill wider access

Teva Pharmaceuticals is preparing for a second round of talks with the US Food and Drug Administration (FDA) regarding whether the Plan B One-Step morning-after emergency contraceptive pill can be sold without a prescription to younger women and girls.

Currently, only those who are 17 and older can buy it without a doctor’s order, Reuters.com reported.

Initially approved in 1999, Plan B contains a higher dose of the progestin hormone that is widely used in birth control pills.

Plan B’s two-pill version taken within 72 hours is now facing generic rivals.

Supporters of contraceptive pills say they aid in the reduction of unwanted pregnancies or abortions by making them easily accessible for girls and women of all ages. However, critics opine that they could lead to promiscuity and sexual abuse.

Teva has given the FDA additional data from a study of actual use of the pill by girls aged from 11 to 16, and is hoping that the agency gives a ruling within 10 months, reported the news agency.